Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.

Roberta Mazzeo,L Bortot,A. Michelotti,S. Buriolla,L. Palmero,Alessandra Franzoni,E Bertoli,G. Targato,Lorenzo Allegri,Lucia Da Ros,Martina Alberti,Paola Di Nardo,Marta Bonotto,Sara Sodde,Barbara Belletti,Simon Spazzapan,Gustavo Baldassarre,Giuseppe Damante,Lorenzo Gerratana,Fabio Puglisi

Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.

2021

e13008Background: Liquid biopsy-based biomarkers, including circulating tumor DNA (ctDNA), are increasingly important for the characterization of metastatic breast cancer (MBC). Currently, CA15.3 i...

Keywords:

Internal medicine
Medicine
Oncology
in patient
Hormone receptor
Metastatic breast cancer
HER2 negative
tumor burden
Liquid biopsy
Circulating tumor DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations